Regulatory
Greenwich Rx Recalls Compounded Semaglutide, Tirzepatide and Peptide Injectables for Lack of Sterility Assurance
On November 20, 2026, Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas, announced a voluntary nationwide recall of specific lots of compounded sterile injectables, including compounded semaglutide and tirzepatide combinations and a long list of peptides, over a potential lack of sterility assurance identified after an FDA inspection. The recall reaches the consumer level and covers products dispensed from August 10 to September 21, 2026.
Quick answer
On November 20, 2026, Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas, announced a voluntary nationwide recall of specific lots of compounded sterile injectables over a potential lack of sterility assurance found after an FDA inspection and the pharmacy's own review. The recalled lots span the telehealth injectable menu, including compounded semaglutide and tirzepatide combinations and many peptides, and the recall reaches the consumer level. Greenwich Rx says it has found no evidence of contamination and received no adverse event reports tied to this recall.
Key takeaways
- →Greenwich Rx, in Tomball, Texas, is voluntarily recalling specific lots of compounded sterile injectables to the consumer level for a potential lack of sterility assurance. The FDA posted the company's announcement on November 20, 2026.
- →The recalled products cover the categories commonly sold through telehealth: compounded semaglutide and tirzepatide combinations (the active ingredients in GLP-1 drugs), NAD+, PT-141, and many peptides including BPC-157, TB-500, KPV, MOTS-C, epithalon, DSIP and semax.
- →The recall followed an FDA inspection and the pharmacy's own evaluation. Greenwich Rx says it has not identified evidence of contamination and has received no adverse event reports connected to this recall, and is acting as a precaution.
- →Affected products were dispensed nationwide between August 10 and September 21, 2026, and include some lots that Greenwich Rx compounded for another pharmacy, Clove Rx. Customers of either pharmacy should check their labels against the product and lot list.
- →It is Greenwich Rx's second recall in two months. In October 2026 it recalled compounded glutathione for potential elevated endotoxin levels after two patients needed emergency care following intravenous use.
A compounding pharmacy that supplies the kind of injectables now common on weight-loss and peptide telehealth platforms has pulled a broad slice of its catalog off the market. On November 20, 2026, the FDA posted a voluntary nationwide recall from Greenwich Rx, a 503A compounding pharmacy in Tomball, Texas, covering specific lots of compounded sterile injectables because of a potential lack of sterility assurance. The recall reaches the consumer level and includes some products that Greenwich Rx compounded for a second pharmacy, Clove Rx.
The company says the concern surfaced after an FDA inspection of the pharmacy and its own review of the affected products, that it has not found evidence of contamination, and that it has received no reports of adverse events tied to this recall. It frames the action as precautionary.
What Greenwich Rx recalled
The recall covers specific lots of compounded sterile injectables that are still within their beyond-use dates. Greenwich Rx's recall notice lists roughly 30 injectable formulations and a lot table that runs to 261 lots. Only affected lots are included, and the recall extends to the consumer level, meaning patients who were dispensed the products, not just clinics and distributors, are asked to act.
The affected products were dispensed nationwide between August 10 and September 21, 2026. Greenwich Rx says it is notifying its own customers by mail, and that some of the recalled products were compounded for Clove Rx.
Why the products were recalled
The stated reason is a potential lack of sterility assurance, a process finding rather than a confirmed case of contamination. According to the recall notice, the concern arose after an FDA inspection of the pharmacy and Greenwich Rx's own evaluation of the affected products. The company says it has not identified evidence of contamination and has received no adverse event reports related to this recall, and is recalling the lots as a precaution.
The risk the notice describes is the general hazard of a product meant to be sterile that may not be. In its words, use of a drug product intended to be sterile that is not sterile could result in serious infections, which it adds may be life-threatening. These injectables are given subcutaneously or intramuscularly, routes that bypass the body's normal barriers to infection.
Which telehealth medications are affected
The recalled list reads like the standard menu of telehealth injectables. It includes compounded semaglutide and tirzepatide combinations, the active ingredients in branded GLP-1 drugs, paired with additives such as B12, glycine, methylcobalamin or L-carnitine. It includes NAD+, PT-141, glutathione, and lipotropic (Lipo-B and Lipo-C) injections.
The largest group is peptides. The list names BPC-157 and TB-500, alone and in multi-ingredient blends with GHK-Cu and KPV, plus MOTS-C, epithalon, DSIP, semax, selank, thymosin alpha-1, and the growth-hormone secretagogues CJC-1295/ipamorelin, sermorelin and tesamorelin. Several of these are the same peptides at the center of the current federal debate over compounding.
The Clove Rx connection
Greenwich Rx says the recall includes products it compounded for Clove Rx. Its notice does not spell out which specific products or lots moved through Clove Rx, and it advises Clove Rx customers to check their labels against the product and lot list even if they did not receive a direct notice. Patients who ordered compounded injectables through a telehealth brand often never see the name of the pharmacy that filled the prescription, which is why checking the physical label and lot number against the recall list matters.
A second recall in two months
This is the pharmacy's second recall in a short span. On October 1, 2026, Greenwich Rx recalled compounded glutathione injection, 200 mg/mL in 10 mL multidose vials, over potential elevated endotoxin levels. In that case the company reported two patients who needed emergency department care, and the notice tied those events to intravenous use of a product that was not formulated for IV administration. That glutathione was distributed nationwide between June 26 and September 21, 2026.
The November action is broader in scope than the October one, covering many product lines rather than a single drug, and it rests on a sterility-assurance finding rather than a specific contaminant or reported injury.
What this means for telehealth patients
Compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness or quality before they are sold. Sterility of an injectable depends on the compounding pharmacy's own processes, which is exactly what a lack-of-sterility-assurance finding calls into question. The recall is a reminder that the quality of a compounded injectable rests on the facility, not on the brand that marketed it.
The timing is notable. Several of the recalled peptides, including BPC-157, TB-500, KPV, MOTS-C, epithalon and semax, are the same substances covered by the HHS interim policy of enforcement discretion for 503A peptide compounding announced in October 2026. That policy does not approve the peptides and does not vouch for any pharmacy's manufacturing quality; it only signals that HHS does not currently intend to pursue certain compounding. A sterility recall in the same category underscores the gap between legal tolerance for compounding a substance and assurance that a given batch was made safely.
What to do if you have an affected product
Greenwich Rx's notice asks anyone holding the products to compare the product name, lot number and beyond-use date on the label with the recall list, stop using any affected product immediately, and discard it following the guidance at FDA.gov/DrugDisposal. The company directs questions to its recall administrator, Sedgwick, at 888-243-5547 or GreenwichRx6588@sedgwick.com, Monday through Friday, 8:00 AM to 5:00 PM Eastern Time. Patients are told to contact a physician or healthcare provider about any problems that may be related to a product, and to report adverse reactions or quality problems to the FDA's MedWatch program at fda.gov/medwatch.
This article is general information, not medical or legal advice. Anyone who has used one of the recalled lots and has symptoms, or who is unsure whether to stop an ongoing treatment, should speak with a licensed clinician rather than act on a news summary. We will update this piece if the FDA classifies the recall or if new information about affected lots or any adverse events becomes available.
Frequently asked questions
Which products are included in the Greenwich Rx recall?+
Greenwich Rx's recall notice lists roughly 30 compounded sterile injectable formulations, with a lot table of 261 lots, all still within their beyond-use dates. The products include compounded semaglutide and tirzepatide combinations, NAD+, PT-141, glutathione, lipotropic injections, and a range of peptides such as BPC-157, TB-500, KPV, MOTS-C, epithalon, DSIP, semax, selank and thymosin alpha-1. The full product and lot list is on the company's recall page.
Why were the products recalled?+
For a potential lack of sterility assurance, which the company says it identified after an FDA inspection and its own review. It is a precautionary action. Greenwich Rx says it has not found evidence of contamination and has received no adverse event reports tied to this recall. The recall notice warns that, in general, using an injectable intended to be sterile that is not sterile could cause serious, potentially life-threatening infections.
Have people been harmed by the recalled injectables?+
Greenwich Rx says it has received no reports of adverse events connected to this November recall. That is separate from the company's earlier October 2026 glutathione recall, in which it reported two patients who needed emergency care after intravenous use of a product not formulated for IV administration.
I bought compounded peptides or semaglutide through a telehealth service. Could they be affected?+
Possibly, if the prescription was filled by Greenwich Rx or Clove Rx during the distribution window of August 10 to September 21, 2026. Telehealth patients often do not see the dispensing pharmacy's name, so the reliable check is to compare the product name, lot number and beyond-use date on the physical label against the recall list. Clove Rx customers are advised to check even if they received no direct notice.
What should I do with a recalled product?+
Stop using any affected lot, discard it following the disposal guidance at FDA.gov/DrugDisposal, and contact a healthcare provider about any problems that may be related to the product. Questions can go to the recall administrator, Sedgwick, at 888-243-5547 or GreenwichRx6588@sedgwick.com. Adverse reactions or quality problems can be reported to the FDA's MedWatch program.
Is this the same as the earlier Greenwich Rx glutathione recall?+
No. The October 1, 2026 recall was limited to compounded glutathione injection over potential elevated endotoxin levels. The November 20, 2026 recall is broader, covering roughly 30 injectable product lines, and is based on a potential lack of sterility assurance rather than a specific contaminant.
Sources
- 1.Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Sterile Products Due to Lack of Sterility Assurance · U.S. FDA
- 2.Greenwich Rx recall notice and affected product and lot list (November 20, 2026) · Greenwich Rx
- 3.Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels · U.S. FDA